NCT00652639已完成1 期
Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Kali's Clonazepam Tablets 1 mg With That of Klonopin Tablets 1 mg in Healthy Adult Subjects Under Fasting Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 主要终点
- Rate and Extend of Absorption
研究概览
简要总结
To compare the single-dose bioavailability of Clonazepam tablets 1 mg and Klonopin tablets 1 mg
详细描述
To compare the single -dose bioavailability of kali's Clonazepam tablets 1 mg with that of Klonopin tablets 1 mg by Roche pharmaceuticals following a single oral dose under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects selected for this study will be alt least 18 years of age.Females must be of non- childbearing potential (postmenopausal for alt least 6 months or surgically sterile)
- •Each subject shall be given a general physical examination within 28 days of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
- •Each female subject will be given a serum pregnancy test as part of the pre-study process.
- •At the end of the study, the subjects will have an exit evaluation consisting of interim history, global evaluation, and clinical laboratory measurements.
- •Adequate blood and urine samples should be obtained within 28 days before beginning of the first period and at the end of the trail for clinical laboratory.
- •Clinical laboratory measurements will include the following:
- •Hematology: hemoglobin, hematocrit, red blood cell count (with differential)
- •Clinical Chemistry: creatinine, BUN, glucose, SGOT/ AST, SGPT/ALT, bilirubin, and alkaline phosphate.
- •Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood and cells.
- •HIV Screen: (Pre-study only)
- •Hepatitis-B, C Screen: (Pre-study only)
- •Drugs of Abuse Screen: (Pre-study at check -in each dosing period)
- •Electrocardiograms of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.
排除标准
- •Subjects with a history of chronic alcohol consumption (during past 2 years), drug addiction, or serious gastrointestinal, renal, hepatic or cardiovascular disease, tuberculosis epilepsy, asthma, (during pat 5 years), diabetes, psychosis or glaucoma will not be eligible for this study.
- •Subjects whose clinical laboratory test values are outside the normal range may be retested at the discretion of the clinical investigator. If the clinical values are outside the range on retesting, the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
- •Subjects who have a history of allergic response to the class of drug being tested should excluded form the study.
- •All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and check in each dosing period. Subjects found to have urine concentration of any of the tested drugs will not be allowed to participate.
- •Subjects should not have donated blood and/plasma for at least thirty (30) days prior to the first dosing of the study
- •Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
- •Female subjects with childbearing potential will not be allowed to participate.
- •All female subjects will be screened for pregnancy at check in each study period.
研究组 & 干预措施
A
Experimental
Subjects received the kali formulated products under fasting conditions
干预措施: Clonazepam (Drug)
B
Active Comparator
Subjects received the Roche formulated products under fasting conditions
干预措施: Klonopin (Drug)
结局指标
主要结局
Rate and Extend of Absorption
时间窗: 24 Hours
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Bioavailability Study of Clonazepam ODT Under Fasting ConditionsTo Determine Bioequivalence Under Fasting ConditionsNCT00652912Par Pharmaceutical, Inc.32
已完成
1 期
Absolute Oral Bioavailability of RemimazolamBioavailabilityNCT04113564Paion UK Ltd.14
已完成
1 期
BA Study of IMP4297 (20mg vs 10mg) in Healthy Male SubjectsSolid TumorNCT04351165Impact Therapeutics, Inc.18
已完成
1 期
Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) ConditionsHealthyNCT01155908Dr. Reddy's Laboratories Limited48
已完成
1 期
Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Fasting ConditionsHealthyNCT01155895Dr. Reddy's Laboratories Limited54